Risk of stroke in healthy postmenopausal women during and after hormone therapy: A meta-analysis

Menopause

Volumn 21, Issue 11, 2014, Pages 1204-1210

  Gu, Haifeng ^a   Zhao, Xiaohong ^a   Zhao, Xiaoping ^a   Yang, Yunmei ^a   Lv, Xueying ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Hormone therapy; Intervention; Meta analysis; Postintervention; Postmenopause; Stroke; Women

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL;

ARTICLE; CEREBROVASCULAR ACCIDENT; FOLLOW UP; HORMONAL THERAPY; HUMAN; INTERVENTION STUDY; META ANALYSIS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELIABILITY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; ADVERSE EFFECTS; CHEMICALLY INDUCED; ESTROGEN THERAPY; FEMALE; MEDLINE; MIDDLE AGED; QUALITY CONTROL; RISK FACTOR; STROKE; WOMEN'S HEALTH;

ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDLINE; MIDDLE AGED; POSTMENOPAUSE; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; WOMEN'S HEALTH;

EID: 84918526266     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/gme.0000000000000227     Document Type: Article

References (19)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
2. Lobo RA. Where are we 10 years after the Women's Health Initiative? J Clin Endocrinol Metab 2013;98:1771-1780.
3. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: A meta-analysis. BMJ 2005;330:342.
4. Billeci AM, Paciaroni M, Caso V, Agnelli G. Hormone replacement therapy and stroke. Curr Vasc Pharmacol 2008;6:112-123.
5. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: A metaanalysis. Eur Heart J 2008;29:2031-2041.
6. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;7:CD004143.
7. Renoux C, Suissa S. Hormone therapy administration in postmenopausal women and risk of stroke. Womens Health (Lond Engl) 2011;7:355-361.
8. Verhagen AP, de Vet HC, de Bie RA, et al. The Delphi list: A criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998;51:1235-1241.
9. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995;273:199-208.
10. Veerus P, Hovi SL, Fischer K, Rahu M, Hakama M, Hemminki E. Results from the Estonian Postmenopausal Hormone Therapy trial [ISRCTN35338757]. Maturitas 2006;55:162-173.
11. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.
12. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353-1368.
13. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000; 320:1574-1577.
14. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-1045.
15. Henderson VW, Lobo RA. Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric 2012;15:229-234.
16. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: A nested case-control study. BMJ 2010;340:c2519.
17. Shufelt CL, Merz CN, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: Findings from the Women's Health Initiative Observational Study. Menopause 2013;21:260-266.
18. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-866.
19. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.